Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | DRD1 | P21728 | 9/20 | 0.48 |
| ▸ | DRD5 | P21918 | 8/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | DRD3 | P35462 | 6/20 | 0.41 |
| ▸ | DRD4 | P21917 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12628112 | 0.86 | MAOA (0.55) | MAOAMAOBDRD1DRD5SLC6A4 | |
| SCHEMBL24671534 | 0.82 | OGA (0.41) | — | |
| SCHEMBL20079837 | 0.82 | ALDH1A1 (0.40) | — | |
| SCHEMBL1619374 | 0.81 | MAOA (0.52) | MAOAMAOBDRD1DRD5SLC6A4 | |
| SCHEMBL26227089 | 0.80 | DRD1 (0.47) | MAOAMAOBDRD1DRD5SLC6A4 | |
| SCHEMBL12608372 | 0.77 | DRD1 (0.49) | MAOAMAOBDRD1DRD5SLC6A4 | |
| SCHEMBL21393017 | 0.75 | MAOA (0.59) | MAOAMAOBDRD1DRD5SLC6A4 | |
| SCHEMBL21362950 | 0.73 | HRH3 (0.46) | MAOAMAOBDRD1DRD5SLC6A4 | |
| SCHEMBL2616785 | 0.73 | MAOA (0.61) | MAOAMAOBDRD1DRD5SLC6A4 | |
| SCHEMBL25444508 | 0.72 | MAOA (0.50) | MAOAMAOBDRD1DRD5SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |